1. Home
  2. NYXH vs GNLX Comparison

NYXH vs GNLX Comparison

Compare NYXH & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.60

Market Cap

126.0M

Sector

Health Care

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.97

Market Cap

132.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYXH
GNLX
Founded
2009
2001
Country
Belgium
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.0M
132.7M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
NYXH
GNLX
Price
$1.60
$2.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$9.33
$17.25
AVG Volume (30 Days)
490.0K
155.6K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9.47
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
$213.98
N/A
Revenue Next Year
$126.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$2.29
52 Week High
$8.59
$8.54

Technical Indicators

Market Signals
Indicator
NYXH
GNLX
Relative Strength Index (RSI) 31.52 51.84
Support Level $1.26 $2.33
Resistance Level $3.43 $2.97
Average True Range (ATR) 0.19 0.17
MACD -0.04 -0.01
Stochastic Oscillator 18.89 61.46

Price Performance

Historical Comparison
NYXH
GNLX

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: